January 16th. Zacks Research analyst E. Bagri now forecasts that the biopharmaceutical company will post earnings of $1.75 per share for the quarter, up from their prior forecast of $1.72. The consensus estimate for Gilead Sciences’ current full-year earnings is $4.36 per share. Zacks Research...
You are urged to consider statements that include the words may, will, would, could, should, might, believes, estimates, projects, potential, expects, plans, anticipates, intends, continues, forecast, designed, goal or the negative of those words or other comp...
not the history of past prices. the heavy dot accompanying each forecast is the day's market quote when the forecast was made. it splits each range into upside and downside price change prospects. the trends of both market prices and p...
the extent that any such supply does not (A) adversely affect its ability to meet Gilead's forecasted requirements or (B) adversely affect the Gilead Supplier's ability to supply Gilead's requirements, whether or not such requirements are consistent with Gilead's twelve (12) month forecast. ...
You are urged to consider statements that include the words may, will, would, could, should, might, believes, estimates, projects, potential, expects, plans, anticipates, intends, continues, forecast, designed, goal, or the negative of those words or other comparable word...